Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You were never ever in the DCVax-L, you were never considered for it, you never received it, yet you falsely claim to have information about it and to harass investors AND regulators AND King’s College, and you accuse investors of not being well when you were the one who literally was not well.
OK.
You have no business here. You previously admitted you never were part of this trial. You have no information about this trial. You are pretending to be various things from a patient, who was rejected from the trial, to a complainant against King’s College and now you’re claiming to have been a regulator.
Personally, I think you’re an obsessed crazy person with just enough coherence and psychopathy, to keep your little scam here going. But the reality is you have zero information. And you keep trying to fool retail investors otherwise.
The company “plants” nothing. Quit it with your fake short nonsense. If the company is “planting” stuff, go to the SEC and get them put into jail. But you and I know you know that you can’t. All you can do is post false garbage here and pretend to be in the know and hope some nine will believe you.
There is no one plan. All of these trials are driven by individual doctors and companies seeking funding and doing their thing and justifying it by their own research. There’s no single plan. What are you referring to with SWOG? There is no great conspiracy. That is not how this works.
Not really a big deal. Completely election driven. As soon as the election is over, assuming he wins reelection, it will be renewed or renewed in the lame duck period so the next President, whoever it is can claim credit.
https://www.usatoday.com/story/opinion/voices/2024/05/05/biden-cancer-moonshot-initiative-congress-funding/73525016007/
Absolutely. It can happen. We’ve seen it happen. But I don’t count on markets to operate normally at these levels. In fact, I count on them NOT to operate as they are supposed to in order to find unusual opportunities. We know shorts and MM’s scratch each other’s backs and so too do some writers in this space get involved in that nonsense. Success with a deep financial meaning is the ultimate validator. Sometimes it had to have immediate meaning or shorts are going to play with longs to get as much of the value for themselves as they can.
No, just pushes aside the shot piled on the stock for years.
You could say the same for approval by regulatory agencies in your world. Quite frequently approval leaves a stock flat or even going down these days, but the undeniable fact is, that company has gone from pre-revenue to commercial. The best example I can give is Regeneron. After approval it stayed flat for around a year. Was it irrelevant that the FDA approved what became their most important drug approval? Obviously NOT.
The markets are often off, misinformed and unable to judge the future because of shorts and their immense work to misinform the market.
Big events that change the narrative of a drug and company can be something a stock market might not note but every competitor and potential partner might take immense interest in and that can open the door to negotiations that can be quiet, take a while and change the false direction of things that had been set by false narratives told over and over and over again by interests and people who had contrary interests and far more immediate resources.
They don’t have customers that are remotely close to commercialization, so they do not have the technology, regardless of claims. They are CDMOs, their job is to claim they can do it, then, when they get paid, figure it out. Not the same situation at all.
Funny when you laugh. It usually means the opposite. NWBO is not a CDMO. I do not expect them to enter that space.
Yes, Flaskworks was picked up for a song, because at least for now, NWBO has a huge head start on this particular segment of immunotherapies.
The notion that there are others with far more advanced technology in this particular space is not true. Yes, there are CDMO companies that help other companies just like Advent and its predecessor. Of course there are. But this is the only company going commercial in this space with automation and dendritic cells are a particular, sticky animal. No one else is advanced or has debugged any technology remotely similar for automating a process as complicated as this though I am sure you’ll find some random webpage making such a claim. It’s just not true, and the only company out there has helped with this technology and is likely locked under contract.
The reality is, even those companies that claim t have automated car-t processes have not yet had their technologies fully validated or solves the problem that currently leaves those companies unable to meet demand and with extremely high costs, regardless of claims to the contrary.
But yeah, laugh all you want. It doesn’t change reality. It’s empty.
I agree it was picked up for a song.
Looks like a positive sign of their expectation of going commercial shortly.
Eventually. Narratives never immediately change price. This is just your way of trying to steer the conversation back to nonsense. A change in narrative can be quite subtle after years and years of misinformation.
Attempts to misdirect and steal thunder are always noticed, thank you very much.
Despite your deep desire to MISDIRECT, what all the shorts do around here… your fraud is obvious.
Nonsense. Most of the debt at this level is exactly the same. It has not been “disastrous” for shareholders, their loans have not been in huge amounts. And as I said, they put off financings of course with fingers crossed that something better will happen just ahead and they delay immediate reliance on shares.
As for your nonsensical claim that this has to do with “Toucan”, that’s just more short nonsense. That has absolutely nothing to do with partnerships except this… they can’t take it cheap given the serious interests involved that won’t sell it cheap. Yes, THAT keeps a deal at a cheap valuation from happening. It can also lead to shorts, in the interest of taking a company cheap, to short the crap out of such companies to convince them that there is no value there and they are its only hope. But the fight against such interests is actually great for shareholders in the long-run though it always sucks in the short term because near do wells always want to pretend they are white hats rather than black hats and then to shift blame on the executives for “keeping the valuation low”. But the increasing desperation can be heard in the increasing posts, despite this being a very quiet stick. The activity of shorts is CONSTANT and LOUD.
Let’s be clear what my post originally said. It said it will change the narrative. I did not say it automatically and immediately changes “the price”.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174340836
Not true if the capitalization of the principal is delayed and it gives them more time to have events that could change the valuation.
My sense is that to a large degree, the day-to-day at these tiny biocaps is to push forward the dates of recognition of certain full capital costs, with the hope that the capital context will radically change. It’s therefore still leverage until it is paid off.
I have pointed out before that Regeneron stayed flat after its first approval. But the increasing revenue was undeniable. Within a year it started to climb. But before that, the validation should get this to a more level range of valuation.
I know there are people who do not want this, whatever their reasons. And I can’t predict price anymore than the can. But I can counter opinions that give price predictions as a given. No one saw that price pop to $2.51. NO ONE. So don’t tell me the wise guys around here know at all what they are talking about.
It’s not “academic”. They already have production. Approval means revenue. Nature means broader validation.
Where did that post say anything about LP or geniuses? I missed it.
I understand some have certain expectations and I recognize that this indeed does happen. But no one can really say. It depends on a lot of factors. Predictions either way have mostly been wrong. When it hit $2.51 and stayed about $1.50 and $1.25, whiffs were sure it must go down immediately. Of course, what has hurt is the non-stop silence, and the normal context where a lot of people pile out pre-approval, just in case. It’s a common thing to see price go down in the run-up to an approval and then to take off.
As I said, you have potentially incredible results to publish in a journal like Nature. That will transform narratives. What does that mean? It means a lot more speculation on deals and buyouts. That transforms the hunger for the stock, especially one so undervalued.
But yeah, could pop and then go back down. Just about anything can happen in microcap land. If they literally had hens who laid golden eggs, probably there would be piles of skeptics trying to short and talk down the process, first saying no such thing existed, then claiming that they would upset the market price for gold and therefore it’s very bad thing.
The shorts in each of those companies took the opportunity to mess with those innovative companies and spread false information because the opportunity to profit was believed to be easy. It's technical, and retail, shorts believe, is stupid.
It works better for small, not yet validated biotechs.
Shorts are a menace to the world. A person can legitimately short a portfolio holding. That's a reasonable way to manage the downside risk if they anticipate something they own was bought at too high a price or if there are macro events that will drive that value down.
But the shorts that manipulate markets and sentiment and spread false light narratives are criminals who leverage our constitutional protections to do harm to society and other investors for profit, spits and giggles.
Oh nonsense. They are all over the place as the microcap level. They are constantly being shorted and attacked by opportunists who think they can take them over like Martin Shkreli. And some have garbage and stay valued highly for years before they crash, because they are being milked by investment funds and their friends taking investor money and playing with them.
Your insight is really not very insightful.
And yeah, there was not an ecosystem developing the CDMO space for this exact product, and so she invested in other people creating it, and they sold, and she bought the retained expertise as part of her spinoff rights so that she could maintain the SAME company effectively, for manufacturing through approval.
But the company owns Flaskworks, and that is the obvious future. They also have the full economic control of Sawston except for those parts that will be used to meet their requirements for local regional development financing, which was low cost, but requires that they provide CDMO services to other, local researchers and companies at Cambridge and in that region.
But yeah, according to shorts it's all criminal even though they are top lawyers who had extremely responsible positions in government and could be making way more money doing other things, with no cares.
Such fricking idiocy. But yeah, it's in your economic interest to spread this nonsense. And of course, UCLA, doctors at top research institutions in immunotherapy including University of Pennsylvania and Brown University, don't agree with you. But you're the anonymous expert online telling people how it really is. Pffft! nonsense! Get lost.
They are likely to be approved. Assuming approval, they have done an immense job keeping their expenses low, their manufacturing scale-up costs low. They are not "dendreon" though the idiot shorts made that bet 10 years ago and they won't let go... but it's a bad bet. This technology is way better at every level, and is breakthrough. Companies do go bankrupt, with fantastic technology as well, and as I said, that is ALWAYS the risk in these small biotechs. ALWAYS. But the opportunity is that IF they succeed, they have the potential to become extremely valuable. Unlike others, I won't predict the market gets it on any event. But someone will, and that will likely transform the conversation. All IMHO.
Any small biotech can fail. They can also go from zero to billions. That is the whole point. But your scaremongering is empty. Expected and empty.
Nature publication…. Could be just ahead.
That will likely change perception in the marketplace. I can’t say it will bring in institutions, but it could substantially change the narrative, overnight.
Actually, you exaggerate the number of years since completion by 2. What’s new?
And yes, the trial was completed. It started before most immunotherapy trials, but they ran out of cash in 2008, and restarted. They also learned a lot and across the industry, standards have changed since that time for the evaluating things like PFS from the knowledge that was gained not just by this trial but all the others.
You post somewhere else you’re “buying today”. You’re just a swing trader with multiple accounts.
Nonsense. It is already doing all the things intended, you’re just unaware. NWBO is not yet in a position to benefit from the clauses I was referencing that address directly and clearly the comment. Additionally, the regulator has already implemented those provisions. It’s not just the law but the implementation.
Just because some people here have misrepresented what it is, out of perhaps enthusiasm and a bit of unsophistication, your comment much the same, it doesn’t annul the law.
As for Car-T, myself have posted at length on the subject of Car-T and NICE… I don’t recall your posts on the subject. DCVax-L does not reflect the issues that caused Car-T to be limited in application.
By the way, 1) the cures act is about more than RMAT; 2) I have owned and then got out of RMAT designated trials just in time before they failed; and 3) RMAT was not what I was referring to and since you did not reply on topic given your previous post and my response with 21st Century Cures Act, you do not seem fully cognizant of what it provides.
Nice try.
I am not here to advocate your investment in anything nor to explain how markets work to you. A decline in market price can be due to many things. Stocks go up and down, often not for any particular reason at that company. If you haven’t noticed, a lot of good companies declined quite a bit over the last few days. Macro and micro economic events can be the cause.
You clearly are not paying attention to the 21st Century Cures Act or what that means for new labels and insurance coverage yes, for data only gotten through real world examples.
You have no idea what you’re talking about.
If that were true, and this were nothing 1) I’d expect you to show much more professionalism and to be much more competent; and 2) I would not expect you to be wasting your time here trying to annoy investors in a small company. You should have better things occupying your time if you were vaguely competent at your job that complaining on this board and wasting everyone’s time with your nonsense.
It’s not up to the company. It’s UCLA’s trial. Hopefully they will be fast.
I suppose the NIH support and research with millions of dollars is nothing. But yeah, no support.
Successful administration. The sleepy guy in court is scharting himself awake periodically.
He doesn’t have a “fear”. He just posts for the obvious purpose of constantly dissuading anyone from investing.
Name calling is for the people who actually have nothing to say. You pervert the truth in some instances. But generally speaking, you tell lies daily.
Of course this is a false description, but that never stops you. PFS is only for early approval. It is a surrogate measure for survival. But with immunotherapies, especially brain tumors, early on the methods for determining recurrence did not take into account the actual response to an immunotherapy, which, duh, causes inflammation, which looks like a flair on a scan, but is actually the drug working. They can’t take back those designations, but when everyone is living longer, a lot longer in certain instances, that is a survival benefit and that would make PFS in this instance, the old way of measuring it, not a valid surrogate for survival and therefore not a valid measure of failure or success in any way.
Subsequently, PFS has been adjusted, PFS+6, for instance, but this trial was already started and far along.You can’t adopt a newer PFS plus that may be flawed as well. Hence, better measures have evolved and NO, they couldn’t just throw in some ORR, at that point. That’s ridiculous and stupid and shows you have no idea of what you post.
They got permission to make OS primary, and to use a very thoroughly vetted, externally proposed, expertized, blinded placebo based on concurrent trials that has the same placebo standard of care.
You can invent all you want. You can look to doctors with competitive treatments to make the argument based often on ignoring key parts of the trial, and details.
But the reality is, virtually all the other drugs that have been approved have in fact actually failed, at one point or another and still been approved based on other data. This trial does not have those problems.
People post those screen shots regularly. Yours doesn’t show your ID. No way to know if that is true. And we know the rest of what you wrote is flatly false.
I don’t believe they have it in that form, that it is available to personnel who would be doing such work or that it is available generally in the way the suit suggests. For their broad claims, depending on the judge, and they likely brought it somewhere in a favorable forum, they might even be successful in undermining regulation, and market surveillance. But the unfortunate likelihood is that they are just making the SEC more blind, and that is the purpose of the suit. And the SEC is definitely not going to suddenly start doing anything remotely as you suggest particularly but not likely because of the suit you point to…
I think your description of the game is a far more accurate one Beartrap, and a more likely unfortunate outcome. I agree that it is in the day-to-day manufacturing of a market and settlement back and forth, that that “naked short” market exists. They fill orders without the shares, back and forth to each other, they roll the FTD’s forward filling the ones at the end or later in the process first, and they ultimately settle up, likely regularly, for unaccounted shares that were not going to any real retail accounts in the end anyway. In the overall process, their big clients get “favorable pricing”…